Skip to main content
SpringerLink
Log in

Risk Factors and Biomarkers of RA-ILD

  • Chapter
  • First Online:
Lung Disease in Rheumatoid Arthritis

Part of the book series: Respiratory Medicine ((RM))

Abstract

Interstitial lung disease (ILD) is one of the most common clinical manifestations of lung involvement in rheumatoid arthritis (RA). It is often progressive and leads to substantial morbidity and mortality, highlighting the need for improved recognition of disease, including identification of targets for disease prevention and clinical tools that classify early stages of disease. Recent research has identified risk factors for both early-stage and clinically evident RA-ILD, including those significantly associated with disease progression and mortality. Furthermore, recent advances in experimental protein biomarkers of RA-ILD and their incorporation into clinical predictive models may lead to earlier identification of disease and provide opportunities for timely interventions to prevent disease progression. Although the research exploring molecular and genetic markers of RA-ILD is limited, the overlap of RA-ILD with idiopathic pulmonary fibrosis and other connective tissue disease-ILD, such as systemic sclerosis, enables extrapolation from ongoing research in these areas, thus highlighting other potential targets for discovery and opportunities for a personalized approach to RA-ILD risk assessment and management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46:350–7.

    Article  CAS  Google Scholar 

  2. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011;183:372–8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis associated interstitial lung disease. Arthritis Rheumatol. 2017;69(3):542–9.

    Article  CAS  PubMed  Google Scholar 

  4. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

    Article  PubMed  PubMed Central  Google Scholar 

  5. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165:277–304.

    Article  Google Scholar 

  6. Kim E, Collard H, King TJ. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest. 2009;136:1397–405.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004;232:81–91.

    Article  PubMed  Google Scholar 

  8. Assayag D, Elicker BM, Urbania TH, et al. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270:583–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Assayag D, Lubin M, Lee JS, King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014;19:493–500.

    Article  PubMed  Google Scholar 

  10. Kim E, Elicker B, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35:1322–8.

    Article  CAS  PubMed  Google Scholar 

  11. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4:443–8.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bongartz T, Nannini C, Medina-Velasquez Y, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010;62:1583–91.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Crestani B. The respiratory system in connective tissue disorders. Allergy. 2005;60:715–34.

    Article  CAS  PubMed  Google Scholar 

  14. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012;185:1147–53.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364:897–906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156:528–35.

    Article  CAS  PubMed  Google Scholar 

  17. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med. 2008;168:159–66.

    Article  CAS  PubMed  Google Scholar 

  18. Dawson J, Fewins H, Desmond J, Lynch M, Graham D. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61:517–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762–84.

    Article  CAS  PubMed  Google Scholar 

  20. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.

    Article  PubMed  CAS  Google Scholar 

  21. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

    Article  PubMed  CAS  Google Scholar 

  22. Risk factors, World Health Organization. 2017. Web: http://www.who.int/topics/risk_factors/en/. Accessed Dec 2016.

  23. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology (Oxford). 2014;53:1676.

    Article  CAS  Google Scholar 

  24. Doyle TJ, Dellaripa PF, Batra K, et al. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest. 2014;146:41–50.

    Article  PubMed  Google Scholar 

  25. Weyand CM, Schmidt D, Wagner U, Goronzy JJ. The influence of sex on the phenotype of rheumatoid arthritis. Arthritis Rheum. 1998;41:817–22.

    Article  CAS  PubMed  Google Scholar 

  26. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:729–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008;105:13051–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Dai J, Cai H, Li H, et al. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology. 2015;20:947–52.

    Article  PubMed  Google Scholar 

  29. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62:1576–82.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Esposito DB, Lanes S, Donneyong M, et al. Idiopathic pulmonary fibrosis in United States automated claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med. 2015;192:1200–7.

    Article  PubMed  Google Scholar 

  31. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol. 2013;25:360–6.

    Article  CAS  PubMed  Google Scholar 

  32. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136–42.

    Article  CAS  PubMed  Google Scholar 

  33. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:1390–4.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Solomon JJ, Chung JH, Cosgrove GP, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016;47:588–96.

    Article  PubMed  Google Scholar 

  35. Saag K, Kolluri S, Koehnke R, et al. Rheumatoid arthritis lung disease: determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39:1711–9.

    Article  CAS  PubMed  Google Scholar 

  36. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the pulmonary scientific Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2006;25:745–55.

    Article  PubMed  Google Scholar 

  37. Doyle TJ, Patel AS, Hatabu H, et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers. Am J Respir Crit Care Med. 2015;191:1403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kallberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70:508–11.

    Article  PubMed  Google Scholar 

  39. Antoniou KM, Hansell DM, Rubens MB, et al. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am J Respir Crit Care Med. 2008;177:190–4.

    Article  PubMed  Google Scholar 

  40. Vassallo R, Ryu J. Tobacco smoke-related diffuse lung diseases. Semin Respir Crit Care Med. 2008;26:643–50.

    Article  Google Scholar 

  41. Patel R, Ryu J, Vassallo R. Cigarette smoking and diffuse lung disease. Drugs. 2008;68:1511–27.

    Article  PubMed  Google Scholar 

  42. Baumgartner K, Samet J, Stidley C, Colby T, Waldron J. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997;155:242–8.

    Article  CAS  PubMed  Google Scholar 

  43. Malik S, Saravanan V, Kelly C. Interstitial lung disease in rheumatoid arthritis: an update on diagnosis and management. Int J Clin Rheumatol. 2012;7:297–308.

    Article  CAS  Google Scholar 

  44. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38–46.

    Article  CAS  PubMed  Google Scholar 

  45. Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem. 2008;41:1074–7.

    Article  CAS  PubMed  Google Scholar 

  46. Padyukov L, Silva C, Stolt P, Alfredsson L, Klareskog L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 2004;50:3085–92.

    Article  CAS  PubMed  Google Scholar 

  47. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.

    Article  Google Scholar 

  48. Doyle TJ, Pinto-Plata V, Morse D, Celli B, Rosas IO. The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest. 2012;142:1027–34.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Luukkainen R, Saltyshev M, Pakkasela R, Nordqvist E, Huhtala H, Hakala M. Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis. Scand J Rheumatol. 1995;24:119–20.

    Article  CAS  PubMed  Google Scholar 

  50. Harlow L, Rosas IO, Gochuico BR, et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65:869–79.

    Article  CAS  PubMed  Google Scholar 

  51. Fischer A, Solomon JJ, du Bois RM, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106(7):1040.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Kaminski R, Wollebo HS, Datta PK, White MK, Amini S, Khalili K. Interplay of Rad51 with NF-kappaB pathway stimulates expression of HIV-1. PLoS One. 2014;9:e98304.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  53. Ganesan V, Schmidt B, Avula R, et al. Immuno-proteomics: development of a novel reagent for separating antibodies from their target proteins. Biochim Biophys Acta. 2015;1854:592–600.

    Article  CAS  PubMed  Google Scholar 

  54. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep. 2010;12:363–9.

    Article  PubMed  Google Scholar 

  55. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med. 2008;5:623–33.

    Article  CAS  Google Scholar 

  56. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;185:67–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013;143:1422–9.

    Article  CAS  PubMed  Google Scholar 

  58. Prasse A, Pechkovsky DV, Toews GB, et al. CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis Rheum. 2007;56:1685–93.

    Article  CAS  PubMed  Google Scholar 

  59. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:717–23.

    Article  CAS  PubMed  Google Scholar 

  60. Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135:1557–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Takahashi H, Fujishima T, Koba H, et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med. 2000;162:1109–14.

    Article  CAS  PubMed  Google Scholar 

  62. Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:155–61.

    CAS  PubMed  Google Scholar 

  63. Greene KE, King TEJ, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002;19:439–46.

    Article  CAS  PubMed  Google Scholar 

  64. Chen J, Doyle T, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2015;67:28–38.

    Article  CAS  Google Scholar 

  65. Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity: sialylated carbohydrate antigen KL-6. Chest. 1989;96:68–73.

    Article  CAS  PubMed  Google Scholar 

  66. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology. 2006;11:164–8.

    Article  PubMed  Google Scholar 

  67. Kinoshita F, Hamano H, Harada H, et al. Role of KL-6 in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT. Respir Med. 2004;98:1131–7.

    Article  PubMed  Google Scholar 

  68. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307:L681–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Kashiwabara K. Characteristics and disease activity of early interstitial lung disease in subjects with true parenchymal abnormalities in the posterior subpleural aspect of the lung. Chest. 2006;129:402–6.

    Article  PubMed  Google Scholar 

  70. Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K. The radiological patterns of interstitial change at an early phase: over a 4-year follow-up. Respir Med. 2010;104:1712–21.

    Article  PubMed  Google Scholar 

  71. Collard HR, Calfee CS, Wolters PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299:L3–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Furuhashi K, Suda T, Nakamura Y, et al. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med. 2010;104:1204–10.

    Article  PubMed  Google Scholar 

  73. Kono M, Nakamura Y, Suda T, et al. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta. 2011;412:2211–5.

    Article  CAS  PubMed  Google Scholar 

  74. Pardo A, Selman M. Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc. 2006;3:383–8.

    Article  CAS  PubMed  Google Scholar 

  75. Yanaba K, Hasegawa M, Takehara K, Sato S. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol. 2004;31:1112–20.

    CAS  PubMed  Google Scholar 

  76. Elhaj M, Charles J, Pedroza C, et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol. 2013;40:1114–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Hoffmann-Vold AM, Tennoe AH, Garen T, et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest. 2016;150:299–306.

    Article  PubMed  Google Scholar 

  78. Kuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol. 2016;43:1825–31.

    Article  CAS  PubMed  Google Scholar 

  79. Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine L, Danoff SK, Oddis CV. Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev. 2010;6:108–19.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Harlow L, Gochuico BR, Rosas IO, et al. Anti-citrullinated heat shock protein 90 antibodies identified in bronchoalveolar lavage fluid are a marker of lung-specific immune responses. Clin Immunol. 2014;155:60–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Schmidt K, Martinez-Gamboa L, Meier S, et al. Bronchoalveolar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther. 2009;11:R111.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  83. Meloni F, Caporali R, Marone Bianco A, et al. BAL cytokine profile in different interstitial lung diseases: a focus on systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21:111–8.

    PubMed  Google Scholar 

  84. Chu SG, El-Chemaly S, Rosas IO. Genetics and idiopathic interstitial pneumonias. Semin Respir Crit Care Med. 2016;37:321–30.

    Article  PubMed  Google Scholar 

  85. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013;5:205ra136.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011;157:191–9.

    Article  CAS  PubMed  Google Scholar 

  87. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Eng J Med. 2011;364:1503–12.

    Article  CAS  Google Scholar 

  88. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368:2192–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Nogee LM. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu Rev Physiol. 2004;66:601–23.

    Article  CAS  PubMed  Google Scholar 

  90. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004;59:977–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Diaz de Leon A, Cronkhite J, Yilmaz C, et al. Subclinical lung disease, Macrocytosis and premature graying in Kindreds with telomerase (TERT) mutations. Chest. 2011;140:753–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet. 2008;45:654–6.

    Article  CAS  PubMed  Google Scholar 

  93. Liu T, Ullenbruch M, Choi YY, et al. Telomerase and telomere length in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013;49:260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1:309–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Zhu L, Wang L, Luo X, et al. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-beta signaling pathway. J Biol Chem. 2012;287:39653–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Hodgson U, Pulkkinen V, Dixon M, et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet. 2006;79:149–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2013;188:1442–50.

    Article  PubMed  CAS  Google Scholar 

  98. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:588–94.

    Article  PubMed  Google Scholar 

  99. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One. 2010;5:e8959.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  100. Kang YP, Lee SB, Lee JM, et al. Metabolic profiling regarding pathogenesis of idiopathic pulmonary fibrosis. J Proteome Res. 2016;15:1717–24.

    Article  CAS  PubMed  Google Scholar 

  101. Spagnolo P, Tzouvelekis A, Maher TM. Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med. 2015;21:470–8.

    Article  CAS  PubMed  Google Scholar 

  102. Maher TM. PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery. Eur Respir Rev. 2013;22:148–52.

    Article  PubMed  Google Scholar 

  103. Steyerberg E. Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer; 2009.

    Book  Google Scholar 

  104. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.

    Article  CAS  PubMed  Google Scholar 

  105. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–42.

    Article  CAS  PubMed  Google Scholar 

  106. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.

    Article  CAS  PubMed  Google Scholar 

  107. Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1065–72.

    Article  CAS  PubMed  Google Scholar 

  108. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–9.

    Article  PubMed  Google Scholar 

  109. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156:684–91.

    Article  PubMed  Google Scholar 

  110. Ryerson CJ, Vittinghoff E, Ley B, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2013;144:234.

    Article  PubMed  Google Scholar 

  111. Baker JF, Conaghan PG, Smolen JS, et al. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with MRI synovitis and x-ray progression. Arthritis Rheum. 2013;66(4):794–802.

    Article  Google Scholar 

  112. Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2014;74:998.

    Article  PubMed  CAS  Google Scholar 

  113. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248–54.

    Article  PubMed  Google Scholar 

  114. Sathi N, Urwin T, Desmond S, Dawson JK. Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease. Rheumatology (Oxford). 2011;50:620.

    Article  Google Scholar 

  115. Rosas IO, Dellaripa PF, Lederer DJ, Khanna D, Young LR, Martinez FJ. Interstitial lung disease: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc. 2014;11(Suppl 3):S169–77.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    Tracy J. Doyle MD, MPH & Ivan O. Rosas MD

  2. Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    Paul F. Dellaripa MD

Authors
  1. Tracy J. Doyle MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul F. Dellaripa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan O. Rosas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy J. Doyle MD, MPH .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Division of Pulmonary Sciences and Critical Care, Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA

    Aryeh Fischer

  2. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA

    Joyce S. Lee

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Doyle, T.J., Dellaripa, P.F., Rosas, I.O. (2018). Risk Factors and Biomarkers of RA-ILD. In: Fischer, A., Lee, J. (eds) Lung Disease in Rheumatoid Arthritis. Respiratory Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-68888-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68888-6_5

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-68887-9

  • Online ISBN: 978-3-319-68888-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation